Trend — Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, (G2083) in Medicare, the United States
Trend · G2083 · National · CY2024
Trend: Growing
Twelve-year services series · G2083 · the United Statesincluded in Explore
The full twelve-year services and payments series for this market — per-year values, with the FFS-enrollment denominator beside each.
Compound growth · endpointsincluded in Explore
The compound annual growth for G2083 in the United States — endpoints exclude the introduction year; an Exclude 2020–21 view drops the pandemic years too.